JAK2V617F 而非 CALR 突变通过 JAK1/STAT1 激活使干扰素-α 的分子学缓解增加
该研究回顾性分析接受聚乙二醇干扰素-α 治疗的骨髓增殖性肿瘤患者,发现 JAK2V617F 突变者较 CALR 突变者更易获得部分分子学缓解(p=0.004),而血液学缓解无显著差异。体外实验显示 JAK2V617F 阳性细胞干扰素刺激基因上调更明显,需更高剂量才能在 CALR 突变细胞达到相同干扰素反应,机制涉及 JAK1/STAT1 组成性磷酸化。
要点
- JAK2V617F 突变骨髓增殖性肿瘤患者接受聚乙二醇干扰素-α 治疗时,部分分子学缓解率高于 CALR 突变者(p=0.004)。
- 体外实验中 CALR 突变细胞达到与 JAK2V617F 突变细胞相同干扰素反应需要更高干扰素-α 剂量。
- JAK2V617F 突变细胞中 JAK1 和 STAT1 呈组成性磷酸化,提示对干扰素-α 反应处于致敏状态。
核心结论
- 数据提示 CALR 突变患者较 JAK2V617F 阳性患者临床上需要更高剂量的干扰素-α,并提出 JAK2V617F-JAK1/STAT1 交互作用致敏 JAK2V617F 阳性细胞从而产生差异敏感性的模型。
研究设计与样本
- 回顾性分析接受聚乙二醇干扰素-α 治疗的骨髓增殖性肿瘤患者,并比较 JAK2V617F 与 CALR 突变细胞的干扰素-α 治疗效果及差异反应机制。
- 体外实验使用 JAK2V617F 阳性 32D 细胞、CALR 突变 32D 细胞以及患者样本(外周血单个核细胞和 CD34+ 造血干细胞)。
主要发现
- 回顾性分析显示 JAK2V617F 突变患者较 CALR 突变患者更易获得部分分子学缓解(p=0.004),血液学缓解无显著差异。
- 体外实验证实 JAK2V617F 阳性 32D 细胞及患者样本(外周血单个核细胞和 CD34+ 造血干细胞)较 CALR 突变对应细胞干扰素刺激基因上调。
- 在 32D 细胞中,CALR 突变细胞达到与 JAK2V617F 突变细胞相同干扰素-α 反应需要更高干扰素-α 剂量。
- JAK2V617F 突变细胞中 JAK1 和 STAT1 呈组成性磷酸化,而 CALR 突变细胞无此现象。
- 干扰素诱导的生长停滞可被选择性 JAK1 抑制所抵消,而被 JAK2 抑制所增强。
关键数值与推荐
- 接受聚乙二醇干扰素-α 治疗的骨髓增殖性肿瘤患者中,部分分子学缓解在 JAK2V617F 突变者较 CALR 突变者更常见(p=0.004)。
- 血液学缓解在 JAK2V617F 突变者与 CALR 突变者之间无显著差异。
临床怎么用
- 作者认为 CALR 突变患者较 JAK2V617F 阳性患者临床上需要更高剂量的干扰素-α。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30-40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F- vs. calreticulin (CALR)-mutated cells and investigated the mechanisms of differential response. Retrospective analysis of MPN patients treated with peg-IFNa demonstrated that patients harboring the JAK2V617F mutation were more likely to achieve PMR than those with mutated CALR (p = 0.004), while there was no significant difference in hematological response. In vitro experiments confirmed an upregulation of IFN-stimulated genes in JAK2V617F-positive 32D cells as well as patient samples (peripheral blood mononuclear cells and CD34+ hematopoietic stem cells) compared to their CALR-mutated counterparts, and higher IFNa doses were needed to achieve the same IFNa response in CALR- as in JAK2V617F-mutant 32D cells. Additionally, Janus-activated kinase-1 (JAK1) and signal transducers and activators of transcription 1 (STAT1) showed constitutive phosphorylation in JAK2V617F-mutated but not CALR-mutated cells, indicating priming towards an IFNa response. Moreover, IFN-induced growth arrest was counteracted by selective JAK1 inhibition but enhanced by JAK2 inhibition. In conclusion, our data suggest that, clinically, higher doses of IFNa are needed in CALR-mutated vs. JAK2V617F-positive patients and we suggest a model of JAK2V617F-JAK1/STAT1 crosstalk leading to a priming of JAK2V617F-positive cells to IFNa resulting in differential sensitivity.
引用
- Czech J, Cordua S, Weinbergerova B, et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia. 2018. PMID: 30470838. doi:10.1038/s41375-018-0295-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。